• Sign In / Register
  • Help
  • Basket0
Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 - Developments in Oncology 27 (Paperback)
  • Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 - Developments in Oncology 27 (Paperback)
zoom

Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 - Developments in Oncology 27 (Paperback)

(editor), (editor)
£114.00
Paperback 112 Pages / Published: 05/10/2011
  • We can order this

Usually despatched within 3 weeks

  • This item has been added to your basket
Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus- cular and subcutaneous routes. Clinical toxicity principally involves the 'influen- za like' syndrome previously seen with native interferons. Other important toxi- cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non- Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea- ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna- tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

Publisher: Springer-Verlag New York Inc.
ISBN: 9781461296188
Number of pages: 112
Weight: 207 g
Dimensions: 235 x 155 x 7 mm
Edition: Softcover reprint of the original 1st ed. 198

You may also be interested in...

Oxford Handbook of Clinical Haematology
Added to basket
£34.99
Part-work (fascículo)
Lecture Notes: Oncology
Added to basket
Cancer Virus
Added to basket
The Cancer Survivor's Companion
Added to basket
Beating Cancer with Nutrition
Added to basket
Cancer
Added to basket
£12.50
Paperback
Survival Lessons
Added to basket
The Emperor of All Maladies
Added to basket
Nature's Cancer-Fighting Foods
Added to basket
The Biology of Cancer
Added to basket
How Football Saved My Life
Added to basket
Laws of Medicine
Added to basket
Beat Cancer
Added to basket
£14.99
Paperback

Reviews

Please sign in to write a review

Your review has been submitted successfully.